1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow CD19 t-haNK- IV Administration: new trials by email Literature Review of CD19 t-haNK- IV Administration trials Research Report on CD19 t-haNK- IV Administration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803, rituximab - Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2026-04-01 | 2026-03-17 |
| Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma CD19 t-haNK- IV Administration - Relapsed B-Cell Non Hodgkin Lymphoma | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-11 | 2026-05-04 |
Lymphoma, B-Cell (2)
South Africa (1)